The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $11.40

Today's change-0.10 -0.87%
Updated July 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $11.40

Today's change-0.10 -0.87%
Updated July 29 4:00 PM -4GMT. Delayed by at least 15 minutes.

Vanda Pharmaceuticals Inc down (U.S.)$0.10

Vanda Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$0.10 or 0.87% to (U.S.)$11.40. Over the last five days, shares have gained 1.69% and 22.45% year to date. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $11.43
  • Previous close(U.S.) $11.50
  • High(U.S.) $11.60
  • Low(U.S.) $11.32
  • Bid / Ask(U.S.) $10.70 / (U.S.) $0.00
  • YTD % change+22.45%
  • Volume374,412
  • Average volume (10-day)454,314
  • Average volume (1-month)493,357
  • Average volume (3-month)547,792
  • 52-week range(U.S.) $6.91 to (U.S.) $14.50
  • Beta1.65
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.96
Updated July 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.21%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue33322828
Total other revenue--------
Total revenue33322828
Gross profit27262222
Total cost of revenue6676
Total operating expense46473833
Selling / general / administrative29291818
Research & development89106
Depreciation / amortization3333
Interest expense (income), net operating--------
Unusual expense (income)--0----
Other operating expenses, total--------
Operating income-12-15-10-5
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-12-15-9-5
Income after tax-12-15-9-5
Income tax, total--------
Net income-12-15-9-5
Total adjustments to net income--------
Net income before extra. items-12-15-9-5
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-12-15-9-5
Inc. avail. to common incl. extra. items-12-15-9-5
Diluted net income-12-15-9-5
Dilution adjustment------0
Diluted weighted average shares43434242
Diluted EPS excluding extraordinary itemsvalue per share-0.29-0.35-0.22-0.13
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.29-0.35-0.22-0.13